<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129582</url>
  </required_header>
  <id_info>
    <org_study_id>CASE9Z13</org_study_id>
    <nct_id>NCT02129582</nct_id>
  </id_info>
  <brief_title>Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>Phase I Trial of Escalated Doses of Targeted Marrow Irradiation (TMI) Combined With Fludarabine and Busulfan as Conditioning Regimen for Allogeneic Hematopoietic Progenitor Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of targeted marrow irradiation when&#xD;
      given with fludarabine phosphate and busulfan before donor progenitor cell transplant in&#xD;
      treating patients with hematologic malignancies. Targeted marrow irradiation is a type of&#xD;
      specialized radiation therapy that delivers a high dose of radiation directly to the cancer&#xD;
      cells, which may kill more cancer cells and cause less damage to normal cells. Giving&#xD;
      targeted marrow irradiation and chemotherapy drugs, such as fludarabine phosphate and&#xD;
      busulfan, before a donor progenitor cell transplant may help stop the growth of cancer cells.&#xD;
      It may also stop the patient's immune system from rejecting the donor's progenitor cells.&#xD;
      When the healthy progenitor cells from a donor are infused into the patient they may help the&#xD;
      patient's bone marrow make progenitor cells, red blood cells, white blood cells, and&#xD;
      platelets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose of targeted marrow irradiation given in&#xD;
      combination with fludarabine (fludarabine phosphate) and busulfan as conditioning regimen for&#xD;
      allogeneic hematopoietic progenitor cell transplantation.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the toxicity profile of the conditioning regimen of targeted marrow&#xD;
      irradiation (TMI), fludarabine and busulfan for allogeneic hematopoietic progenitor&#xD;
      transplantation.&#xD;
&#xD;
      II. To describe the use of two techniques of delivering TMI, volumetric modulated arc therapy&#xD;
      (VMAT) and TomoTherapy, on patient's computed tomography (CT) simulation images and describe&#xD;
      differences in organ avoidance and target coverage, planning time, and treatment delivery&#xD;
      time.&#xD;
&#xD;
      III. To determine the disease response status 100 days after allogeneic hematopoietic&#xD;
      progenitor cell transplantation with the conditioning regimen of TMI, fludarabine and&#xD;
      busulfan.&#xD;
&#xD;
      IV. To determine the rates of acute graft versus host disease after allogeneic hematopoietic&#xD;
      progenitor cell transplantation with the conditioning regimen of TMI, fludarabine and&#xD;
      busulfan.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of TMI.&#xD;
&#xD;
      CONDITIONING: Patients undergo TMI twice daily (BID) on days -10 to -7. Patients also receive&#xD;
      fludarabine phosphate intravenously (IV) over 1 hour on days -6 to -2 and busulfan IV or&#xD;
      orally (PO) on days -5 and -4.&#xD;
&#xD;
      TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.&#xD;
&#xD;
      GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on&#xD;
      days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper&#xD;
      beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 100 days, 6 months, and 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2014</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of targeted marrow irradiation defined as the dose level immediately below that in which greater than or equal to 2/6 subjects experience a dose limiting toxicity assessed using NCI CTCAE version 4.0</measure>
    <time_frame>Up to day 32</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities assessed using NCI CTCAE version 4.0</measure>
    <time_frame>Up to day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient mortality</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ avoidance</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be compared between the two techniques of delivering TMI (VMAT and TomoTherapy) using patients' CT simulation images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target coverage</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be compared between the two techniques of delivering TMI (VMAT and TomoTherapy) using patients' CT simulation images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Planning time</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be compared between the two techniques of delivering TMI (VMAT and TomoTherapy) using patients' CT simulation images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment delivery time</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be compared between the two techniques of delivering TMI (VMAT and TomoTherapy) using patients' CT simulation images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response status, assessed by standard criteria for the presence of relapse</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of acute GVHD, graded and staged according to the Blood and Marrow Transplant Clinical Trials Network Manual of Operations</measure>
    <time_frame>Up to 100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Hematologic Malignancies</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelofibrosis</condition>
  <condition>Myeloproliferative Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING: Patients undergo TMI BID on days -10 to -7. Patients also receive fludarabine phosphate IV over 1 hour on days -6 to -2 and busulfan IV or PO on days -5 and -4.&#xD;
TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.&#xD;
GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total marrow irradiation</intervention_name>
    <description>Undergo TMI</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>myeloid progenitor cell transplantation</intervention_name>
    <description>Undergo allogeneic hematopoietic progenitor cell transplant</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
    <other_name>MPCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ineligible to receive full myeloablative conditioning regimen for allogeneic&#xD;
             hematopoietic progenitor cell transplant due to age or comorbidities&#xD;
&#xD;
          -  Patients must have histologically or cytologically diagnosis of hematologic&#xD;
             malignancies with an indication for allogeneic hematopoietic progenitor cell&#xD;
             transplantation, who are ineligible to receive a full ablative conditioning regimen as&#xD;
             part of their transplantation, including:&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
               -  Acute lymphocytic leukemia&#xD;
&#xD;
               -  Non Hodgkin lymphoma&#xD;
&#xD;
               -  Hodgkin lymphoma&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Myelodysplastic syndrome&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
               -  Chronic myeloid leukemia:&#xD;
&#xD;
               -  Myeloproliferative syndromes including myelofibrosis&#xD;
&#xD;
          -  Complete remission is not necessary for enrollment in this protocol&#xD;
&#xD;
          -  Patients must have an allogeneic hematopoietic progenitor cell donor (HPCT), either a&#xD;
             matched sibling, mismatched (1 allele) sibling, or a matched unrelated donor (MUD) or&#xD;
             a mismatched (1 allele) unrelated donor&#xD;
&#xD;
               -  Previous hematopoietic progenitor cell transplantation is allowed; a minimum of 6&#xD;
                  months should have elapsed from prior autologous hematopoietic progenitor cell&#xD;
                  transplantation and a minimum of 6 months should have elapsed since prior&#xD;
                  allogeneic hematopoietic progenitor cell transplantation; prior transplantation&#xD;
                  with conditioning regimens using total body irradiation is not allowed&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Life expectancy of &gt; 12 weeks, in the opinion of and as documented by the investigator&#xD;
&#xD;
          -  Patients must have adequate hepatic, and renal function as defined below: there is no&#xD;
             exclusion for the presence of cytopenias&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times the institutional upper limit of normal&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])&#xD;
                  ≤ 2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤&#xD;
                  2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  Creatinine clearance (calculated by the Cockroft-Gault formula) ≥ 60 ml/min&#xD;
&#xD;
               -  Pulmonary Function Tests (FEV1, FVC, DLCO) 40%.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (double barrier method of birth control or abstinence) from the time of study entry,&#xD;
             for the duration of study participation and for 3 months after completing treatment;&#xD;
             should a woman become pregnant or suspect that she is pregnant while she or her&#xD;
             partner is participating in this study, she should inform the treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Subjects must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior non-hematologic treatment toxicities must be resolved to ≤ grade 1 according to&#xD;
             National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)&#xD;
             version 4.0, with the exception of the following grade 2 toxicities: alopecia; dry&#xD;
             skin; spleen disorders, hearing impairment; tinnitus; hypothyroidism; hyperthyroidism;&#xD;
             endocrine disorders; blurred vision; cataracts; constipation; gastroesophageal reflux;&#xD;
             fatigue; abnormal coagulation tests INR and/or aPTT; weight gain or weight loss;&#xD;
             anorexia; glucose intolerance; hypoalbuminemia; hypokalemia; muscle weakness;&#xD;
             dysgeusia; paresthesias; peripheral motor and/or sensory neuropathy; hot flashes;&#xD;
             hypertension.&#xD;
&#xD;
          -  Patients must not have received other investigational agents within 14 days of&#xD;
             initiation of the conditioning regimen&#xD;
&#xD;
          -  Patients with untreated brain metastases should be excluded from this clinical trial&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to fludarabine and or busulfan or other agents used in this study&#xD;
&#xD;
          -  Prior allogeneic hematopoietic progenitor cell transplantation&#xD;
&#xD;
          -  Prior autologous hematopoietic progenitor cell transplantation if the conditioning&#xD;
             regimen included total body irradiation&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements; this exclusion criterion does not include the&#xD;
             underlying disease for which the patient is undergoing hematopoietic progenitor cell&#xD;
             transplantation&#xD;
&#xD;
          -  Pregnant or breastfeeding women are excluded from this study; breastfeeding should be&#xD;
             discontinued&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
&#xD;
          -  Patients with a history of therapy with radiation therapy are excluded&#xD;
&#xD;
          -  Due to technical limitations of TMI, patients must be no taller than 1.9 m (6 feet 4&#xD;
             inches), and no wider from elbow to elbow in the supine position than 60 cm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Molly Gallogly, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

